{"id":490,"date":"2024-11-07T16:15:31","date_gmt":"2024-11-07T16:15:31","guid":{"rendered":"https:\/\/stemvacs.therapeuticsolutionsint.com\/?page_id=490"},"modified":"2024-11-07T16:16:13","modified_gmt":"2024-11-07T16:16:13","slug":"melanoma-stemvacs-l","status":"publish","type":"page","link":"https:\/\/stemvacs.therapeuticsolutionsint.com\/index.php\/melanoma-stemvacs-l\/","title":{"rendered":"Melanoma – StemVacs-L"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.21.0″ _module_preset=”default” background_color=”gcid-3cfc8c0c-5557-4a5d-9dab-24e78d615311″ custom_padding=”61px|||||” collapsed=”on” global_colors_info=”{%22gcid-3cfc8c0c-5557-4a5d-9dab-24e78d615311%22:%91%22background_color%22%93}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.24.3″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”-47px|||||” custom_padding=”2px||0px|||” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n

The following list of cancer immunotherapies<\/strong> are available for licensing under U.S. Patent Publication No.: 20220096542<\/span><\/a>.<\/span><\/p>\n

Augmentation of Natural Killer Cell Activity and Induction of Cytotoxic Immunity Using Leukocyte Lysate Activated Allogeneic Dendritic Cells: StemVacs<\/strong><\/p>\n

Abstract
Stimulation of immunity would be beneficial in various chronic conditions such as viral infections and neoplasia. Autologous dendritic cell therapy has been widely described in the immunotherapy literature and has been approved by the FDA for treatment of prostate cancer. Unfortunately, the need to generate individual doses is costly and limited by ability of the patients to have sufficient starting cell numbers available to generate sufficient dendritic cells. Here we describe the process of preparing allogeneic dendritic cells utilizing a leukocyte lysate based approach. These data support development of StemVacs for conditions that would benefit from NK activation such as cancer and COVID-19..<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”-99px|auto||auto||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.24.3″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.24.3″ _module_preset=”default” custom_margin=”-149px|||||” custom_padding=”43px|||||” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]
\n
\n